The present study aimed to develop and evaluate Dolutegravir and Rilpivirine tablets for effective management of HIV infection. The tablets were formulated using different excipients and evaluated for various parameters including hardness, friability, disintegration time, and drug content. The optimized formulations were subjected to in vitro dissolution studies to assess the dissolution rate. Furthermore, an in vivo pharmacokinetic study was conducted in healthy Wistar rats to determine the pharmacokinetic parameters and bioavailability of the formulated tablets. The results showed that the tablets formulated with specific excipients exhibited desirable physical properties and drug content. In vitro dissolution studies revealed satisfactory dissolution rates of the tablets. The in vivo pharmacokinetic study demonstrated favorable pharmacokinetic parameters such as peak plasma concentration, area under the curve, mean residence time, and relative bioavailability. The enhanced bioavailability of the tablets could be attributed to improved solubility and dissolution of the drugs, leading to faster absorption. Overall, the developed Dolutegravir and Rilpivirine tablets showed promising formulation characteristics, dissolution profiles, and pharmacokinetic behavior, indicating their potential for effective HIV management.

Dolutegravir, Rilpivirine, tablets, formulation development, evaluation, in vitro dissolution, in vivo pharmacokinetics, bioavailability, HIV management